In this minority of clinicopathological RCC subtypes where phase III randomized studies are lacking, preferred frontline therapy consists of a VEGFR TKI, usually either cabozantinib or sunitinib, particularly in papillary tumors, although outcomes are usually inferior compared to ccRCC (11, 54, 91). This evidence concerns the gene KDR and renal cell carcinoma.